April 16, 2024
Featured Latest News

Trials for a Two-Dose COVID-19 Vaccine to be Tested by Reliance Life Sciences

The drug regulatory authorities authorised Reliance Life Sciences’ proposal to conduct clinical trials of its recombinant protein-based Covid-19 vaccine candidate on Thursday.

Reliance Life Sciences is part of India’s largest private-sector organisation. Reliance had requested permission from the agency to undertake a Phase 1 trial of its proposed two-dose vaccination. Reliance hopes to learn about medication safety, tolerability, pharmacokinetics, and mechanism of action in Phase 1.

According to a source familiar with the situation, Phase 1 trials typically last 58 days, after which Reliance might apply for Phase 2 and 3 trials. Reliance Life Sciences is yet to make an official announcement. Reliance’s vaccine initiatives come at a time when the country’s vaccination rate is increasing.

Pic Courtesy: google/ images are subject to copyright


Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *